Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Direct correction of haemoglobin E / beta-thalassaemia using base editors

ABSTRACT: Haemoglobin E (HbE)/β-thalassaemia causes approximately 50% of all severe thalassaemia worldwide; equating to around 30,000 births per year. HbE/β-thalassaemia is due to a point mutation in codon 26 of the human HBB gene on one allele (GAG; glutamate → GAA; lysine, E26K), and any mutation causing severe β-thalassaemia on the other. When inherited together in compound heterozygosity these mutations can cause a severe thalassaemic phenotype. However, if only one allele is mutated individuals are carriers for the respective mutation and have an asymptomatic phenotype (β-thalassaemia trait). Here we describe a base editing strategy which corrects the HbE mutation either to wildtype (WT) or a normal variant haemoglobin (E26G) known as Hb Aubenas and thereby recreates the asymptomatic trait phenotype. We have achieved editing efficiencies in excess of 85% in primary human CD34+ cells. We demonstrate editing of long-term repopulating haematopoietic stem cells (LT-HSCs) using serial xenotransplantation in NSG mice. We have profiled the off-target effects using a combination of CIRCLE-seq and deep targeted capture and have developed machine-learning based methods to predict functional effects of candidate off-target mutations.

ORGANISM(S): Homo sapiens

PROVIDER: GSE206098 | GEO | 2023/01/25

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Haemoglobin E beta thalassaemia in a patient group from Sri Lanka

Project description:Exome sequencing of 32 patient samples from Sri Lanka with the condition haemoglobin E beta thalassaemia

| EGAS00001000626 | EGA

EGAS00001000626-sc-20160608 - samples

Project description:Exome sequencing of 32 patient samples from Sri Lanka with the condition haemoglobin E beta thalassaemia

| EGAD00001002185 | EGA

Disrupting the adult-globin promoter alleviates promoter competition and reactivates foetal-globin gene expression

Project description:The benign condition Hereditary Persistence of Foetal Haemoglobin (HPFH) is known to ameliorate symptoms when co-inherited with beta-haemoglobinopathies, such as sickle cell disease and beta-thalassaemia. The condition is sometimes associated with point mutations in the foetal globin promoters that disrupt the binding of the repressors BCL11A or ZBTB7A/LRF, which have been extensively studied. HPFH is also associated with a range of deletions within the beta-globin locus that all reside downstream of the foetal HBG2 gene. These deletional forms of HPFH are poorly understood and are the focus of this study. Numerous different mechanisms have been proposed to explain how downstream deletions can boost the expression of the foetal globin genes, including the deletion of silencer elements, of genes encoding non-coding RNA, and bringing downstream enhancer elements into proximity with the foetal globin gene promoters. Here we systematically analyse the deletions associated with both HPFH and a related condition known as beta-thalassaemia and propose a unifying mechanism. In all cases where foetal globin is up-regulated, the proximal adult beta-globin (HBB) promoter is deleted. We use CRISPR gene editing to delete or disrupt elements within the promoter and find that virtually all mutations that reduce promoter activity, result in elevated foetal globin expression. These results fit with previous models where the foetal and adult globin genes compete for the distal Locus Control Region and suggest that targeting the promoter might be explored to elevate foetal globin and reduce sickle globin expression as a treatment for beta-haemoglobinopathies.

2022-01-20 | GSE194064 | GEO

Differential gene expression in erythroid progenitor cells from β-thalassaemia patients and healthy controls [Bioconductor/limma R analysis]

Project description:This study uses microarray technology to examine the erythroid progenitor mRNA of patients with transfusion dependent β-thalassaemia and compare it to erythroid progenitor mRNA from healthy controls. We observed no statistical difference in gene expression between the groups following 7 days in culture. However, following 14 days in culture we observed differential expression of 161 genes. Haematopoietic cells from the peripheral blood of 6 β-thalassaemia patients and 6 healthy controls was grown in semi-solid media. After 7 and 14 days in culture cells of erythroid origin were isolated. Total RNA was isolated from these for microarray gene expression analysis

2014-10-28 | E-GEOD-62430 | biostudies-arrayexpress

Regulation of alpha-like globin gene expression in murine primitive erythropoiesis (ATAC-seq)

Project description:Haemoglobin, the oxygen-carrying molecule of red blood cells, at all stages of development comprises a tetramer of two α-like and two β-like globin chains. In humans and mice the highly conserved α- and β-globin loci contain genes encoding globin chains specifically expressed only during the first trimester of gestation (termed embryonic globins) in addition to the genes encoding globin chains expressed throughout adult life. In humans the β-globin locus also encodes a β-like chain that is expressed throughout the second and third trimesters of development; this is termed γ-globin and complexes with α-globin to form fetal haemoglobin (HbF). The sequential activation and repression of the genes at each of these loci throughout development to maturity is termed haemoglobin switching and is a poorly understood process. α-thalassemia, which results from insufficient production of α-globin, is a major global health problem with several hundred thousand sufferers world-wide. The embryonically expressed ζ-globin, encoded by the gene HBZ (Hba-x in mice), can functionally substitute for α-globin in adult erythroid cells. Reactivation of this gene is consequently likely to ameliorate the symptoms of α-thalassemia in individuals with a severe phenotype. Little is currently known about the regulation of ζ-globin expression in terms of both the trans- and cis-acting regulatory elements responsible for high-levels of expression of this gene during embryonic erythropoiesis and its maintenance in a transcriptionally inactive state throughout adult life. Using ATACseq and NG Capture C and mutant mouse lines this work aims to identify and define the cis-acting regulatory network underlying zeta-globin expression, and define the contribution of each regulatory element.

2021-05-06 | GSE108430 | GEO

Regulation of alpha-like globin gene expression in murine primitive erythropoiesis (NG CaptureC)

2021-05-06 | GSE108432 | GEO

Regulation of alpha-like globin gene expression in murine primitive erythropoiesis (ChIP-seq)

Project description:Haemoglobin, the oxygen-carrying molecule of red blood cells, at all stages of development comprises a tetramer of two α-like and two β-like globin chains. In humans and mice the highly conserved α- and β-globin loci contain genes encoding globin chains specifically expressed only during the first trimester of gestation (termed embryonic globins) in addition to the genes encoding globin chains expressed throughout adult life. In humans the β-globin locus also encodes a β-like chain that is expressed throughout the second and third trimesters of development; this is termed γ-globin and complexes with α-globin to form fetal haemoglobin (HbF). The sequential activation and repression of the genes at each of these loci throughout development to maturity is termed haemoglobin switching and is a poorly understood process. α-thalassemia, which results from insufficient production of α-globin, is a major global health problem with several hundred thousand sufferers world-wide. The embryonically expressed ζ-globin, encoded by the gene HBZ (Hba-x in mice), can functionally substitute for α-globin in adult erythroid cells. Reactivation of this gene is consequently likely to ameliorate the symptoms of α-thalassemia in individuals with a severe phenotype. Little is currently known about the regulation of ζ-globin expression in terms of both the trans- and cis-acting regulatory elements responsible for high-levels of expression of this gene during embryonic erythropoiesis and its maintenance in a transcriptionally inactive state throughout adult life. Using ATACseq, ChIP-seq and NG Capture C and mutant mouse lines this work aims to identify and define the cis-acting regulatory network underlying zeta-globin expression, and define the contribution of each regulatory element.

2021-05-18 | GSE174593 | GEO

The circRNA expression profiles of reticulocytes for β-thalssemia carriers with high fetal hemoglobin

Project description:To explore the involvement of circRNAs in β-thalassemia and their actions on fetal hemoglobin (HbF), we surveyed circRNA expression profiles using circulating reticulocytes isolated from individuals with β-thalassaemia carriers with high HbF.

2022-05-27 | GSE196682 | GEO

Transcriptomic analysis in Suv39h2-deficient brain during early neurodevelopment

Project description:To examine the molecular phenotype of Suv39h2-deficits during early neurodevelopment, transcriptome analysis in the E11.5 brain of Suv39h2-deficient mouse and wild-type littermates were performed. The Suv39h2 mutation was made using CRISPR/Cas9n-mediated genome editing

2023-12-30 | E-MTAB-10528 | biostudies-arrayexpress

ADAR1 Zα domain P195A mutation activates the MDA-5 dependent RNA-sensing signaling pathway in the brain enhanced by haploinsufficiency without overall RNA editing level decrease.

Project description:The A-to-I RNA editing enzyme ADAR1 critically regulates the cellular RNA sensing signaling pathway, as the RNA-sensing signaling pathway recognizes unedited RNAs as “non-self” to activate the innate immune response. Mutations of ADAR1 cause severe inflammatory tissue injury, as shown in Aicardi-Goutières syndrome (AGS), in which severe inflammation occurs in the brain. The most frequent ADAR1 mutation in AGS is the P193A mutation in the Za domain, which exists in the AGS families coupling with an additional ADAR1 mutation. How this mutation alters the cellular RNAs leading to innate immune activation, has not been fully understood. This study analyzed RNA editing status and innate immune activation in the brains of a mouse model that carries the human ADAR1 P193A-equivalent mouse P195A mutation. We found that this mutation alone can cause excessive ISG expression in the brains, especially in the periventricular areas reflecting the pathologic feature of AGS. Furthermore, we found that ADAR1 P195A mutation did not affect the RNA editing activity in the overall RNA editing level; however, it leads to ISG expression in a dose-dependent manner, causing severer innate immune activation in haploinsufficiency status, whereas wildtype ADAR1 is redundant to suppress innate immune activation. The finding from this study indicated that the intact Z-RNA binding activity of ADAR1 plays a critical role in suppressing self-cellular RNA sensing, and innate immune homeostasis requires a minimum Z-RNA binding capacity of ADAR1.

2023-05-31 | GSE229884 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data